Roland Veltkamp received his clinical training as a stroke neurologist in Heidelberg, Germany, and at Wake Forest University School of Medicine, USA. His research interests encompass emergency therapy of ischemic and hemorrhagic stroke and stroke prevention in atrial fibrillation. His research has led to new methods of Afib detection on the stroke unit and to the improvement of acute stroke management in patients on anticoagulants. His translational stroke research group investigates the role of the immune system after stroke. In a landmark study, his group has described a major protective role of regulatory T cells in experimental stroke. Recent findings in his laboratory have led to a phase II clinical stroke trial testing the effect of the leukocyte adhesion blocker natalizumab in stroke.
Currently, Prof. Veltkamp serves as a member of the Board of Directors of the European Stroke Organisation and is an international delegate of the program committee of the AHA International Stroke Conference.
et al., 2022, Novel heterozygous COL4A2 variant c.2572A > G, p.(I858V) mimicking Sneddon's and Divry van Bogaert Syndrome, Journal of Neurology, ISSN:0340-5354
et al., 2022, Ischemic Stroke in orally anticoagulated patients with atrial fibrillation, Acta Neurologica Scandinavica, Vol:145, ISSN:0001-6314, Pages:288-296
et al., 2022, Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial, International Journal of Stroke, ISSN:1747-4930
et al., 2020, Early initiation of direct anticoagulation after stroke in patients with atrial fibrillation., European Journal of Neuroscience, Vol:27, ISSN:0953-816X, Pages:2168-2175
et al., 2020, EARLY INITIATION OF DIRECT ANTICOAGULATION AFTER STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EIDASAF STUDY., SAGE PUBLICATIONS LTD, Pages:547-547, ISSN:1747-4930